Mouwasat Medical Services Company (4002) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 reached SR 764.3 million, up 5.7% year-over-year, driven by growth in medical services.

• Net profit attributable to shareholders rose to SR 197.0 million, a 14.8% increase from Q1 2024.

• Gross profit improved to SR 347.2 million, with a stable gross margin compared to the prior year.

• The group continued expansion projects, with significant investments in property and equipment.

Financial highlights

• Medical services revenue grew to SR 652.2 million, while pharmaceutical sales slightly declined to SR 112.1 million.

• Operating profit increased to SR 213.3 million, up from SR 195.3 million in Q1 2024.

• Basic and diluted EPS rose to SR 0.99 from SR 0.86 year-over-year.

• Cash and cash equivalents at period end were SR 588.4 million, up from SR 426.6 million at year-end 2024.

• Net cash from operating activities was SR 264.5 million, with net cash used in investing activities at SR 135.8 million.

Outlook and guidance

• The group maintains a strong capital position with SR 1,665 million in unutilized credit facilities for future growth.

• Ongoing expansion projects and capital commitments of SR 352.4 million signal continued investment in capacity.